Skip to main content
Clinical Trials/ITMCTR2000003965
ITMCTR2000003965
Recruiting
未知

Study on the curative effect and evidence-based evaluation of traditional Chinese medicine scheme for lumbar disc herniation

Affiliated Hospital of Changchun University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Affiliated Hospital of Changchun University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\.Medical history: with or without a definite history of lumbar injury.
  • 2\.Symptoms and signs: low back pain radiates to buttocks and lower limbs, abdominal pressure increases, such as cough, sneezing, etc; There was tenderness and radiation to the lower limbs, and the lumbar movement was limited; There may be hypersensitivity or dullness in the affected innervated area of the lower limbs. Muscle atrophy may occur in patients with a long course of the disease. Tendon reflex and dorsiflexion of the toe may be weakened.
  • 3\.Physical examination: positive muscle strength and sensation test; Straight leg raising or strengthening test was a positive result.
  • 4\.Auxiliary examination: MRI showed lumbar disc herniation.
  • 5\.The patient was aged between 18 and 70 years old. The clinical symptoms were leg pain extending below the knee, which was consistent with the corresponding nerve root distribution area of the MRI.
  • 6\.The first course of low back pain or leg pain was less than 3 months, or the latest acute recurrence time was less than 3 months.
  • 7\.This study will compare the efficacy and safety of Chinese patent medicine and Western medicine in the treatment of lumbar disc herniation.
  • 8\.The VAS scores of lumbocrural pain were more than or equal to 4\.0\.

Exclusion Criteria

  • 1\. The patient had a history of lumbar surgery;
  • 2\. Patients have received oral or epidural steroid therapy in recent 3 months;
  • 3\. Severe diabetes with peripheral neuropathy, severe osteoporosis, gastric ulcer, gastrointestinal bleeding, spinal tumor, spinal tuberculosis, spinal compression fracture;
  • 4\. Allergic to non\-steroidal drugs;
  • 5\. There are symptoms of cauda equina nerve damage or parenchymal and progressive loss of motor function;
  • 6\. Patients with litigation or legal claims.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
The construction of an overall evaluation method for the clinical efficacy of TCM and western medicine in co-constructing parallel medical records
ITMCTR1900002299Beijing Institute of Traditional Chinese Medicine Clinical Epidemiology and Evidence-Based Medicine Center
Not yet recruiting
Phase 1
The clinical investigation of the curative effect about Nai-Lao-Kang combination with antituberculotics in MDR-TB
ITMCTR2000003501Chongqing Zhihui Institute of Traditional Chinese Medicine
Not yet recruiting
Phase 1
Study on the clinical curative effect and mechanism of ''Jiawei Huanshao Dan'' on senile frailty syndromesenile frailty syndrome
ITMCTR2100005078CHINA-JAPAN FRIENDSHIP HOSPITA
Active, not recruiting
Not Applicable
A study to investigate belimumab for the treatment of chronic immune thrombocytopeniaChronic Immune ThrombocytopeniaMedDRA version: 15.1Level: LLTClassification code 10051057Term: Idiopathic thrombocytopeniaSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2011-000241-21-DEGlaxoSmithKline Research & Development Limited40
Active, not recruiting
Not Applicable
A study to investigate belimumab for the treatment of chronic immune thrombocytopeniaChronic Immune ThrombocytopeniaMedDRA version: 14.1Level: LLTClassification code 10051057Term: Idiopathic thrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2011-000241-21-GBGlaxoSmithKline Research & Development Limited40